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Abstract
5′-Methylthioadenosine (MTA) is a naturally occurring sulfur-containing nucleoside present in all mammalian tissues. MTA
is produced from S-adenosylmethionine mainly through the polyamine biosynthetic pathway, where it behaves as a powerful
inhibitory product. This compound is metabolized solely by MTA-phosphorylase, to yield 5-methylthioribose-1-phosphate
and adenine, a crucial step in the methionine and purine salvage pathways, respectively. Abundant evidence has accumulated
over time suggesting that MTA can affect cellular processes in many ways. MTA has been shown to influence numerous
critical responses of the cell including regulation of gene expression, proliferation, differentiation and apoptosis. Although
most of these responses have been observed at the pharmacological level, their specificity makes it tempting to speculate that
endogenous MTA could play a regulatory role in the cell. Finally, observations carried out in models of liver damage and
cancer demonstrate a therapeutic potential for MTA that deserves further consideration.
© 2003 Elsevier Ltd. All rights reserved.
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1. Introduction
The natural existence of the sulfur-containing nucle-
oside methylthioadenosine [5′-deoxy-5′-methylthio-
adenosine; adenine-9--D (5′-deoxy-5′-methylthio)
ribofuranoside], commonly abbreviated as MTA and
occasionally as MeSAdo, was realized almost a cen-
tury ago (Williams-Ashman, Seidenfeld, & Galletti,
1982). Its molecular structure was reported in 1924,
and the biological importance of MTA became ap-
parent in 1952, 1 year before the discovery of its
metabolic precursor S-adenosylmethionine (AdoMet,
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also abbreviated as SAM and SAMe), in studies on
the metabolic interrelationship of methionine and
5-thiomethylribose (Williams-Ashman et al., 1982).
MTA is present in small amounts in all cell types,
including prokaryotes, yeast, plants and higher eu-
karyotes. In mammalian tissues, MTA is mainly
produced during the biosynthesis of polyamines
(Williams-Ashman et al., 1982; Pegg, 1988). For
many years, this nucleoside has received by far much
less attention than its precursor AdoMet. However, in-
formation accumulated over the past two decades evi-
dences a wide variety of potent and specific effects of
MTA upon its interaction with mammalian cells and
tissues. The present review summarizes what is known
about MTA synthesis and degradation, its biological
functions and its potential therapeutic applications.
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Fig. 1. Structure of 5′-methylthioadenosine (MTA).
2. Structure
MTA is a hydrophobic sulfur-containing adenine
nucleoside in which the hydroxyl group in the 5′ posi-
tion of the ribose is substituted by a methylthio moiety
(Fig. 1). This methylthio moiety is derived from the
amino acid methionine, while the rest of the molecule
comes from ATP.
3. Synthesis and degradation
MTA is produced from AdoMet by different pro-
cesses in a variety of organisms (Williams-Ashman
et al., 1982). MTA can be produced by the cleavage
of one of the AdoMet S–C bonds with the concomi-
tant production of homoserine lactone. This process
is catalyzed by AdoMet cyclotransferase, an enzyme
present in yeast, certain bacteria and mammalian
liver (Williams-Ashman et al., 1982). However, little
is known about the quantitative contribution of this
pathway to MTA synthesis. The major source of MTA
in cells is formed from AdoMet during the synthesis
of the polyamines spermine and spermidine (Pegg,
1988; Williams-Ashman et al., 1982). Polyamine
biosynthesis occurs in all mammalian cells, and starts
with the decarboxylation of AdoMet by the enzyme
AdoMet decarboxylase (AdoMetDC). Decarboxylated
AdoMet is a substrate for the aminopropyltransferases.
These enzymes transfer the aminopropyl group of
decarboxylated AdoMet to putrescine forming sper-
midine (spermidine synthase), and subsequently to
spermidine forming spermine (spermine synthase)
(Fig. 2). Therefore, MTA is produced in stoichiomet-
ric amounts to the aminopropyl groups in spermidine
and spermine. AdoMetDC together with ornithine
decarboxylase (ODC) conform the rate-limiting steps
in polyamine biosynthesis, and thus in MTA pro-
duction (Pegg, 1988). In most cells, MTA does not
accumulate in significant amounts. Its concentrations
are around 3 nmol/g of tissue in rat liver, heart, lung
and kidney, being in the same order of magnitude
as those reported for decarboxylated AdoMet and
adenosine (Williams-Ashman et al., 1982). MTA
is rapidly metabolized by 5′-methythioadenosine
phosphorylase (MTAP) to yield adenine (Ade) and
5-methylthioribose-1-phosphate (MTR1P) (Fig. 2).
MTAP is ubiquitously expressed in mammalian tis-
sues, and the reaction it catalyses represents the first
and rate-limiting step in the salvage pathways in which
MTR1P is finally converted into methionine, and Ade
is salvaged to ultimately replenish the AMP and ATP
pools. Consequently, the two metabolites from which
AdoMet and MTA are formed, namely methionine
and ATP, are thus recovered (Williams-Ashman et al.,
1982). Interestingly, MTAP activity has been found
in human and fetal calf serum, but not in sera from
other species such as horse serum (Riscoe & Ferro,
1984). The conversion of MTR1P into methionine
involves a complex set of oxidations via the inter-
mediate 4-methylthio-2-oxobutanoic acid (MTOB)
(Fig. 2). This efficient cycle sustains the high rate of
polyamine synthesis that occurs during cellular pro-
liferation and provides methionine for AdoMet and
protein synthesis. In addition, the removal of accumu-
lating MTA by MTAP is necessary for the cell to carry
out polyamine metabolism, since MTA is a strong
inhibitor of spermine synthase, and to a lesser extent
of spermidine synthase and of ODC (Pegg, 1988;
Pascale, Simile, De Miglio, & Feo, 2002). The inhi-
bition of ODC by MTA can be mediated in part by its
metabolite MTOB, as has been recently demonstrated
in yeast and human tumor cells (Suhbhi et al., 2003).
Metabolism of MTA in tumor cells deserves further
consideration. It has been extensively reported that
many malignant cells lack MTAP activity, and that
cultured MTAP-deficient cells secrete MTA instead of
metabolizing it (Williams-Ashman et al., 1982; Nobori
et al., 1996). Loss of MTAP activity in human tumors
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Fig. 2. Synthesis and metabolism of 5′-methylthioadenosine (MTA) in mammalian cells. The precursor of MTA, AdoMet, is synthesized from
methionine and ATP in a reaction catalyzed by methionine adenosyltransferase (1). Subsequently, AdoMet is decarboxylated by AdoMet
decarboxylase (2). Decarboxylated AdoMet participates in the synthesis of polyamines, which starts with the conversion of ornithine to
putrescine, carried out by ornithine decarboxylase (3). Then, spermidine synthase (4) and spermine synthase (5) transfer the propylamine
group from decarboxylated AdoMet to putrescine and spermidine, respectively, in two sequential reactions. In these two reactions MTA is
formed. MTA is the substrate of 5′-methylthioadenosine phosphorylase (6), which catalyses the first step in methionine and Ade salvage
pathways. Ade is converted into adenosine and then into AMP by the action of Ade-phosphoribosyltransferase (7) and adenosine kinase
(8). The other reaction product of methylthioadenosine phosphorylase, methylthioribose-1-P, is isomerized by aldose-ketose isomerase (9)
to methylthioribulose-1-P. This compound undergoes a complex set of oxidations to give 4-methylthio-2-oxobutanoic acid, which is finally
transaminated to methionine (10).
has been mainly attributed to homozygous deletions
and translocations at the chromosome 9p21 region
(Nobori et al., 1996). As mentioned above, a pri-
mary consequence of the loss of MTAP activity in
cellular metabolism is the impairment in Ade salvage
to form AMP. Hitherto, the transformed cell relies
only on the de novo purine biosynthesis pathway as
a source of adenine nucleotides for DNA synthesis.
This metabolic trait of tumoral cells has attracted much
attention since it may be exploited chemotherapeu-
tically. Blocking of the de novo purine biosynthesis
pathway by antimetabolites such as methotrexate or
l-alanosine would efficiently kill MTAP-deficient tu-
mor cells, while normal cells are rescued due to their
ability to produce Ade through the salvage pathway,
and thus could be protected by MTA treatment. How-
ever, the in vivo efficacy of this strategy may be ham-
pered due to the presence of MTAP in human serum
as we previously mentioned. Another direct conse-
quence of impaired MTAP activity is the intracellu-
lar accumulation of MTA. In spite of the ability of
MTA to permeate the cell membrane, it has been ob-
served that MTAP deficient cells accumulate sufficient
amounts of endogenous MTA to modulate important
cellular responses (see below). Whether the loss of
MTAP plays a role in the tumorigenic process is not
known at present. However, it has been recently re-
ported that reintroduction of this gene in a human
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mammary tumor cell line reversed in part its trans-
formed phenotype (Suhbhi et al., 2003).
4. Biological functions
As can be inferred from above, MTA is located at a
crossroad in cellular metabolism. MTA is a metabolic
product of AdoMet in polyamine biosynthesis, and at
the same time the starting point of two major salvage
pathways. Besides its role as a metabolic intermedi-
ate, MTA may play relevant regulatory functions in
the cell. Some of these functions, such as its inhibitory
effects on spermidine and spermine synthase and on
ODC, have been already outlined. In addition, a wide
variety of biological responses to MTA administration
have been reported both in vivo and in cultured cells.
These effects range from the control of the expression
of specific genes, the inhibition of cell proliferation,
lymphocyte activation, tumor development and inva-
siveness, and the regulation of apoptosis (Ansorena
et al., 2002; Law et al., 1992; Lee & Cho, 1998;
Martı´nez-Chantar et al., 2003; Mato, Corrales, Lu, &
Avil, 2002; Pascale et al., 2002; Williams-Ashman
et al., 1982). Of special interest are the observations
carried out in the liver as well as in normal and trans-
formed cultured hepatic cells. This organ has a remark-
able proliferative potential, and is able to quickly re-
store its mass after partial hepatectomy. This process,
which is triggered by cytokines such as tumor necrosis
factor- (TNF-) that make the hepatocyte responsive
to growth factors like hepatocyte growth factor (HGF),
needs to be tightly controlled and its fundamental
mechanisms are not fully understood (Mato et al.,
2002). Shortly after, partial hepatectomy MTA levels
in the remaining liver parenchyma are significantly
reduced, coinciding with the replicative response of
the hepatocytes (Ferioli & Scalabrino, 1986). Inter-
estingly, exogenous MTA administration to rats after
partial hepatectomy inhibits hepatocyte DNA synthe-
sis (Pascale et al., 2002), and a similar response has
been observed in cultured rat hepatocytes treated with
HGF in the presence of MTA (Mato et al., 2002).
These observations suggest that intracellular fluctua-
tions in MTA levels could participate in the regula-
tion of the liver proliferative response. Furthermore,
in experimental models of chemically induced hep-
atocarcinogenesis, where it has been observed that
MTA levels are reduced (Ferioli & Scalabrino, 1986;
Pascale et al., 2002), administration of MTA induces
a dose-dependent inhibition of preneoplastic liver le-
sions and DNA synthesis (Pascale et al., 2002). The
hepatoprotective effects of MTA have been extended
to a model of CCl4-induced chronic liver damage in
rats. In this experimental setting, that reproduces the
human lesions induced by alcohol and viral infections
of the liver, replenishment of the hepatic pool of MTA
showed strong anti-oxidant effects and reduced liver
cell damage and fibrosis (Pascale et al., 2002). It is
worth mentioning that normal and transformed liver
cells display a differential response to MTA. While
hepatocarcinoma cells undergo apoptosis when treated
with MTA, normal hepatocytes remain viable and,
furthermore, are protected from okadaic acid-induced
programmed cell death (Ansorena et al., 2002). The
mechanisms of this distinct response are not known at
present. One could speculate that the different MTAP
status, and thus the differential ability to metabolize
MTA of normal and transformed hepatocytes, might
have some significance. However, this different be-
havior of normal and transformed hepatocytes may be
behind the chemopreventive and hepatoprotective ef-
fects of MTA.
A common denominator to the development of
liver damage and fibrosis, and the ultimate neoplastic
transformation, is the presence of a chronic inflam-
matory response. Recent observations from our labo-
ratory demonstrate that MTA is a powerful modulator
of inflammation in vivo. The administration of MTA
to mice challenged with lethal doses of bacterial
lipopolysaccharide (LPS) completely prevented death
induced by this toxin (Hevia et al., unpublished obser-
vations). This effect was associated with a substantial
inhibition in the production of the pro-inflammatory
cytokine TNF- and with enhanced production of the
anti-inflammatory cytokine interleukin-10.
Several molecular mechanisms have been proposed
to explain the remarkable effects of MTA on cellu-
lar functions. The inhibition of polyamine synthesis
could be responsible for the cytostatic effects of MTA
or its downstream metabolite MTOB (Suhbhi et al.,
2003). However, additional mechanisms must exist
since the exogenous provision of spermidine does
not always reverse the growth inhibitory effects of
MTA (Williams-Ashman et al., 1982). MTA has been
shown to interfere with key cell signaling pathways.
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It is able to inhibit growth-factor induced protein ty-
rosine phosphorylation and to increase intracellular
cAMP levels through the inhibition of cAMP phos-
phodiesterase (Maher, 1993; Riscoe et al., 1984).
One of the best-characterized actions of MTA is the
inhibition of protein methylation (Williams-Ashman
et al., 1982). This post-translational modification may
occur at arginine residues or at the carboxyl termi-
nus of proteins, and is thought to modulate cellular
signaling and gene expression (Law et al., 1992; Lee
& Cho, 1998; Mowen et al., 2001). MTA may exert
this effect either through the direct interaction with
protein methyltransferases or indirectly through the
inactivation of S-adenosylhomocysteine (AdoHcy)
hydrolase (Williams-Ashman et al., 1982). Inactiva-
tion of AdoHcy hydrolase results in the intracellular
accumulation of AdoHcy, which is also a potent
inhibitor of many methyltransferases (Mato et al.,
2002). To further complicate the understanding of
the cellular responses to MTA, some of the effects
of this molecule on the regulation of gene expression
have been attributed to its ability to replenish the
cellular AdoMet pool through the methionine salvage
pathway (Martı´nez-Chantar et al., 2003).
The fact that most of the above-mentioned
observations have been performed using high con-
centrations of MTA may question their physiological
significance. Nevertheless, a recent report showed that
the presence of excess MTA found in certain cancer
cells is sufficient to inhibit arginine methylation of the
STAT1 transcription factor and consequently to impair
interferon-induced gene transcription (Mowen et al.,
2001).
5. Possible medical applications
MTA is a natural compound with potent pharma-
cological effects. The administration in vivo of high
doses of MTA in experimental models of acute and
chronic liver damage and liver carcinogenesis has
proved to be beneficial, and without major toxico-
logical manifestations. Besides, our unpublished ob-
servations demonstrate a powerful anti-inflammatory
profile for this molecule. Although systematic studies
on the pharmacokinetics and toxicity of MTA are
lacking, and its mechanism or mechanisms of ac-
tion are not completely known (as occurs with many
registered drugs), we believe that the potential thera-
peutic use of MTA in liver and inflammatory diseases
deserves to be explored.
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